Table 2 Relationship of SMC1A expression and clinicopathological parameters in colorectal cancer patients (n = 427)

Gender (n)

Male

21 (8.8%)

128 (53.3%)

80 (33.3%)

11 (4.6%)

Female

20 (10.8%)

79 (42.5%)

82 (44.1%)

5 (2.7%)

Age (years)

≤60

27 (11.9%)

112 (49.3%)

82 (36.1%)

6 (2.6%)

>60

14 (7.0%)

95 (47.7%)

80 (40.2%)

10 (5.0%)

Position

Colon cancer

6 (2.9%)

99 (47.4%)

93 (44.5%)

11 (5.3%)

Rectal cancer

35 (16.1%)

108 (49.8%)

69 (31.8%)

5 (2.3%)

Invasion depth

T1-T2

11 (13.9%)

34 (43.0%)

32 (40.5%)

2 (2.5%)

T3-T4

30 (8.6%)

173 (49.9%)

130 (37.5%)

14 (4.0%)

Lymph node metastasis

N0

10 (4.4%)

107 (46.7%)

103 (45.0%)

9 (3.9%)

N1

19 (14.5%)

65 (49.6%)

41 (31.3%)

6 (4.6%)

N2

12 (18.2%)

35 (53.0%)

18 (27.3%)

1 (1.5%)

Distant metastasis

M0

40 (10.8%)

186 (50.0%)

133 (35.8%)

13 (3.5%)

M1

1 (1.9%)

21 (38.9%)

29 (53.7%)

3 (5.6%)

TNM

I

7 (13.2%)

22 (41.5%)

23 (43.4%)

1 (1.9%)

II

3 (1.9%)

77 (48.4%)

71 (44.7%)

8 (5.0%)

III

30 (18.8%)

87 (54.4%)

39 (24.4%)

4 (2.5%)

IV

1 (1.9%)

21 (38.9%)

29 (53.7%)

3 (5.6%)

Tumor differentiation

Well

1 (7.7%)

7 (53.8%)

5 (38.5%)

0 (0.0%)

Moderately

30 (8.4%)

170 (47.5%)

143 (39.9%)

15 (4.2%)

Poorly

10 (18.2)

30 (54.5%)

14 (25.5%)

1 (1.8%)

Serum CEA

≤5 ng/mL

21 (7.5%)

137 (48.9%)

112 (40.0%)

10 (3.6%)

>5 ng/mL

20 (13.7%)

70 (47.9%)

50 (34.2%)

6 (4.1%)

Serum CA199

≤37 U/ml

31 (8.7%)

176 (49.2%)

138 (38.5%)

13 (3.6%)

>37 U/ml

8 (12.3%)

31 (47.7%)

23 (35.4%)

3 (4.6%)

Recurrence

No

34 (10.1%)

161 (47.6%)

132 (39.1%)

11 (3.3%)

Yes

7 (8.0%)

46 (52.3%)

30 (34.1%)

5 (5.7%)